

WEST PHARMACEUTICAL SERVICES INC

Form 8-K

May 23, 2012

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported) – May 23, 2012

WEST PHARMACEUTICAL  
SERVICES, INC.

(Exact name of registrant as specified in its charter)

Pennsylvania  
(State or other jurisdiction  
of Incorporation)

1-8036  
(Commission File  
Number)

23-1210010  
(IRS Employer  
Identification No.)

101 Gordon Drive, PO Box  
645, Lionville, PA  
(Address of principal  
executive offices)

19341-0645  
(Zip Code)

Registrant's telephone number, including area code: 610-594-2900

Not Applicable  
(Former name or address, if changed since  
last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 7.01. Regulation FD Disclosure

On May 23, 2012, West Pharmaceutical Services, Inc. (the “Company”) will host an Analyst and Investor Day from 8:30 to 11:30 AM EDT in New York, New York. Members of the Company’s senior management will provide an overview of the company’s current markets, operations, and growth opportunities at 9:00 AM EDT.

A copy of the Company’s presentation materials from the Investor Day will be available for 30 days through the Investors link at the Company’s website, <http://www.westpharma.com>, and is also attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (Exchange Act) or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

|                 |                                                                         |
|-----------------|-------------------------------------------------------------------------|
| Exhibit<br>99.1 | West Pharmaceutical Services, Inc. Overview (Investor<br>Presentation). |
|-----------------|-------------------------------------------------------------------------|

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WEST  
PHARMACEUTICAL  
SERVICES, INC.

/s/ John R. Gailey III  
John R. Gailey III,  
Vice President, General  
Counsel and Secretary

May 23, 2012

EXHIBIT INDEX

| Exhibit No. | Description                                                          |
|-------------|----------------------------------------------------------------------|
| 99.1        | West Pharmaceutical Services, Inc. Overview (Investor Presentation). |

